BACKGROUND: Molecular tests have clinical utility for thyroid nodules with indeterminate fine-needle aspiration (FNA) cytology, although their performance requires further improvement. This study evaluated the analytical performance of the newly created ThyroSeq v3 test. METHODS: ThyroSeq v3 is a DNA-and RNA-based next-generation sequencing assay that analyzes 112 genes for a variety of genetic alterations, including point mutations, insertions/deletions, gene fusions, copy number alterations, and abnormal gene expression, and it uses a genomic classifier (GC) to separate malignant lesions from benign lesions. It was validated in 238 tissue samples and 175 FNA samples with known surgical follow-up. Analytical performance studies were conducted. RESULTS: In the training tissue set of samples, ThyroSeq GC detected more than 100 genetic alterations, including BRAF, RAS, TERT, and DICER1 mutations, NTRK1/3, BRAF, and RET fusions, 22q loss, and gene expression alterations. GC cutoffs were established to distinguish cancer from benign nodules with 93.9% sensitivity, 89.4% specificity, and 92.1% accuracy. This correctly classified most papillary, follicular, and Hurthle cell lesions, medullary thyroid carcinomas, and parathyroid lesions. In the FNA validation set, the GC sensitivity was 98.0%, the specificity was 81.8%, and the accuracy was 90.9%. Analytical accuracy studies demonstrated a minimal required nucleic acid input of 2.5 ng, a 12% minimal acceptable tumor content, and reproducible test results under variable stress conditions. CONCLUSIONS: The ThyroSeq v3 GC analyzes 5 different classes of molecular alterations and provides high accuracy for detecting all common types of thyroid cancer and parathyroid lesions. The analytical sensitivity, specificity, and robustness of the test have been successfully validated and indicate its suitability for clinical use. Cancer 2018;124:1682-90.
INTRODUCTION
Thyroid cancer is the most common type of endocrine malignancy, and its incidence has been continuously growing over the last several decades in the United States and many other countries. Thyroid cancer frequently presents as a thyroid nodule. However, thyroid nodules are far more common than cancer, with only a small fraction of all medically evaluated nodular thyroid lesions found to be malignant or even neoplastic. 1, 2 Nevertheless, the growing use of high-resolution imaging propels the detection of more and more thyroid nodules and subsequently thyroid cancer in what some pronounce to be an epidemic of this disease. 3, 4 In thyroid nodules with clinical or ultrasonographic suspicion for malignancy, fine-needle aspiration (FNA) with a subsequent cytological examination of collected cells is typically performed. 2 FNA cytology provides a definitive diagnosis of a benign or malignant nodule in 70% to 75% of cases, whereas the remainder of the aspirates fall into one of three indeterminate-cytology categories defined by the Bethesda system. 5, 6 These include Bethesda categories III, IV, and V, which have expected risks of cancer of 5% to 15%, 20% to 30%, and 50% to 75%, respectively. The uncertainty about the cancer risk of these nodules precludes optimal medical or surgical management of these patients, and many of them undergo diagnostic surgery that could be avoided in many patients with benign nodules.
Over the last decade, molecular testing has been increasingly used to improve diagnosis and optimize the management of patients with thyroid nodules that carry an indeterminate cytological diagnosis. It has progressed from single gene and small gene panels to broad genomic panels, multigene classifiers, and the use of other molecular markers. 7, 8 However, most of these approaches still have not reached the highest possible accuracy for the detection of all the main types of thyroid cancer, and they may have limited performance in the populations with a high pretest probability of cancer. The detection of Hurthle cell (oncocytic) carcinomas remains problematic, particularly for low-grade cancers. In addition, for optimal performance, such diagnostic tests should accurately identify medullary thyroid cancer and nonthyroidal nodular lesions that occur in this location (particularly parathyroid lesions).
Further enhancement of the diagnostic performance can be achieved by the expansion of existing tests and the incorporation of additional, more recently discovered molecular markers of thyroid cancer. Indeed, over the last several years, a number of new driver mutations and gene fusions (GFs) in different types of thyroid cancer have been discovered. [9] [10] [11] [12] [13] Furthermore, it has been shown that a small but distinct proportion of thyroid cancers carry other types of molecular alterations, such as copy number variations. 10, 12 Importantly, the rapid development and improvement of sequencing assays allow the detection of multiple and various types of genetic alterations with a limited amount of cells collected by thyroid FNA. 14 We have previously developed and clinically used a next-generation sequencing (NGS)-based test, ThyroSeq v2, which includes 56 thyroid-related genes analyzed for point mutations, GFs, and abnormal gene expression. 15, 16 In this study, we report the development of a new, 112-gene version of the test. ThyroSeq v3 was built with the goals of 1) expanding the current ThyroSeq v2 test panel through the inclusion of recently discovered genetic markers related to thyroid nodules and cancer, 2) enabling the analysis of additional classes of genetic alterations that were not previously tested (ie, copy number alterations [CNAs]), and 3) improving the test's accuracy for detecting various types of Hurthle cell (oncocytic) tumors. Furthermore, we report the results of the analytical performance studies of the test that are required for its clinical use.
MATERIALS AND METHODS

Tissue and FNA Samples
The study samples included 238 surgically removed, fresh-frozen, and formalin-fixed, paraffin-embedded (FFPE) tissue samples, 175 FNA samples of indeterminate cytology from nodules that were subsequently removed with a known surgical pathology diagnosis, 16 cell lines, and 4 reference controls (Table 1 and Supporting  Table 1 [see online supporting information]). The study was approved by the University of Pittsburgh institutional review board. Pathology glass slides from tissue samples of Hurthle cell lesions were blindly reviewed to verify the diagnosis and subclassify these nodules. with a MagNA Pure instrument (Roche). Nucleic acid concentrations are determined with a GloMax Discover System fluorometer (Promega) and a NanoDrop 8000 spectrophotometer (Thermo Fisher Scientific). NGS libraries are generated from 10 ng of DNA and 10 ng of RNA with Ion AmpliSeq Library Kit 2.0 and Ion Xpress Barcode Adapters, as previously described. 14, 17 The libraries are normalized for template preparation on the Ion Chef and are sequenced on the Ion Proton (Thermo Fisher Scientific) according to the manufacturer's protocol. Torrent Suite software (version 5.2.2; Thermo Fisher Scientific) and software developed in house (Variant Explorer, version 2) are used for data analysis and interpretation.
NGS and Data Analysis
The accuracy of NGS was determined independently for each class of genomic alteration through an analysis of normal and pathogenic reference cell lines, reference sequencing controls, and patient samples with ThyroSeq v3 and an orthogonal method as a gold standard according to current NGS guidelines. 18 The sequencing performance characteristics are reported in Supporting Table 3 (see online supporting information).
Genomic Classifier (GC) Score
Each detected genetic alteration was annotated to receive a value of 0 to 2 based on the strength of its association with malignancy. The values were derived from 1) an extensive literature and searchable database review (eg, The Cancer Genome Atlas, cBioPortal, and the Catalogue of Somatic Mutations in Cancer), 2) an in-house database of more than 1000 thyroid surgical and FNA samples with known surgical outcomes, 3) an RNA-Seq analysis of thyroid cancer tissue and FNA samples, 9,19 and 4) a CytoScan analysis of 17 thyroid cancer tissue samples. The total GC score for each sample was calculated as a sum of individual values of detected genomic alterations:
CNA where x is the weighted value (0-2); n is the number of SNVs/indels; and SNV/I (single-nucleotide variant/ indel), GF, GEA, and CNA are indicators of the genomic alteration type. Table 4 [see online supporting information]).
Statistical Analysis
We calculated empirical sensitivity, specificity, accuracy, and positive and negative predictive values with 95% Wilson confidence intervals (CIs). 20 The true positive fraction (sensitivity) and the false-positive fraction (1 -specificity) were plotted against the false-positive rate in a receiver operating characteristic curve. The area under the curve (AUC) was computed by the trapezoidal method with CIs according to the work of DeLong et al. 21 A 2-step approach was applied. First, the most accurate classifier was tested in the tissue training set. Next, the established score was evaluated in an independent validation set of FNA specimens with known surgical outcomes. For the purpose of these analyses, cases of noninvasive follicular thyroid neoplasm with papillary-like nuclear features (NIFTP) were considered together with malignant nodules because both tumor types require surgical excision. Twenty-five repetitions of 10-fold cross-validation were applied to test the classifier parameter stability in both the training set and the validation set.
RESULTS
ThyroSeq v3 is a 112-gene, DNA-and RNA-based, targeted NGS assay that tests for 5 classes of genetic alterations: 1) point mutations, 2) indels, 3) GFs, 4) CNAs, and 5) GEAs. The complexity of the analysis of the output data necessitated the establishment of a GC to classify the test result as negative (likely benign) or positive (likely malignant; Fig. 1 ).
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Establishing the GC With a Training Set of Tissues
To establish a classifier, ThyroSeq v3 NGS analysis was performed on 238 surgically removed tissue samples. This set consisted of 205 thyroid tissue samples representing all main types of benign and malignant tumors and nontumoral conditions and enriched in tumors negative for common genetic alterations, 13 parathyroid tissue samples, and 20 samples of other tissue types (Table 1) . Overall, cancer-associated point mutations (SNVs) and indels were identified in 55 samples, GFs in 35 samples, CNAs in 47 samples, and GEAs in 105 samples ( Table 2 ). The most commonly detected alterations were SNVs/indels in the BRAF, RAS, EIF1AX, TERT, RET, DICER1, TP53, PTEN, and PIK3CA genes; GFs affecting the RET, PPARG, NTRK1, NTRK3, BRAF, ALK, THADA, and IGF2BP3 genes; CNAs at the 22q and NF2 genomic regions; and GEAs affecting MET, CALCA, and PTH. The GC score was calculated for each sample and was found to range from 0 to 8. A receiver operating characteristic curve revealed an AUC of 93.1% (95% CI, 89.5%-96.8%; Fig. 2A) . A cross-validation analysis revealed similar test performance with an AUC of 91.7%. The most accurate separation between benign and malignant samples was found with the GC score value of 1.5. On the basis of this analysis, a test result yielding a score <1.5 was designated as negative (likely benign), whereas a score 1.5 was designated as positive (likely malignant). With this cutoff, the test sensitivity in the training set was 93.9% (95% CI, 88.4%-96.9%), the specificity was 89.4% (95% CI, 81.1%-94.3%), and the accuracy was 92.1% (95% CI, 87.8%-95.0%). The test correctly classified 52 papillary thyroid carcinomas (91.2%), 27 Hurtle cell (oncocytic) carcinomas (93.1%), and 10 conventional follicular thyroid carcinomas (90.9%). Two NIFTP cases were classified as positive. In addition, 13 parathyroid nodules (100%) and 15 medullary thyroid carcinomas (100%) were correctly detected. All 20 nonthyroidal tissues were identified as being of nonthyroidal origin.
ThyroSeq v3 GC Performance in a Validation Set of FNA Samples
Next, we tested the GC in an independent set of 175 FNA samples of indeterminate cytology (Bethesda III, n 5 84; Bethesda IV, n 5 74; and Bethesda V, n 5 17) and known surgical outcomes (Table 1) . This set was purposely enriched in nodules found to be malignant after surgery, which constituted 52.6% of the set. In this sample set, point mutations and indels were identified in 115 samples, GFs in 1 sample, CNAs in 35 samples, and GEAs in 79 samples. The total GC score ranged from 0 to 6. With the proposed cutoff of 1.5, the ThyroSeq v3 GC revealed a sensitivity of 98.0% (95% CI, 92.9%-99.4%), a specificity of 81.8% (95% CI, 71.8%-88/9%), and an accuracy of 90.9% (95% CI, 85.7%-94.3%). The test receiver operating characteristic curve showed an AUC of 90.6% (95% CI, 85.6%-95.6%; Fig. 2B ). The crossvalidation analysis of the test results in this set of FNA samples revealed a similar AUC of 89.9%.
Performance of the ThyroSeq v3 GC in Hurthle Cell Lesions
One of the goals of creating ThyroSeq v3 was to achieve a robust test performance in Hurthle cell (oncocytic) thyroid nodules. To achieve this goal, the training tissue set Figure 1 . Workflow of the ThyroSeq v3 genomic classifier. Total nucleic acids from FNA or tissue samples are used to prepare and quantitate the DNA and RNA sequencing libraries and to determine the overall sample adequacy. Samples with acceptable adequacy are sequenced. The data analysis starts with an evaluation of the cellular composition of the sample (follicular thyroid cells, parathyroid cells, C cells, or nonthyroidal cells). Then, sequencing data from 112 genes undergo a bioinformatic analysis to detect SNVs, indels, gene fusions, gene expression alterations, and CNAs. Next, the genomic classifier is applied to annotate the detected alterations and generate a score to classify the test result as negative or positive. CNA indicates copy number alteration; FNA, fine-needle aspiration; indel, insertion/ deletion; NGS, next-generation sequencing; QA, quality assurance; SNV, single-nucleotide variant.
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Cancer April 15, 2018 was enriched in all types of oncocytic lesions. Furthermore, a blind re-review of histopathologic slides was performed to provide better separation between Hurthle cell hyperplasia and Hurthle cell adenoma on the basis of histopathological features. The criteria for adenoma included a complete moderately thick to thick capsule and a growth pattern clearly different from adjacent thyroid parenchyma (typically microfollicular or solid; Fig. 3A,B) . Based on the re-review of pathology, the training set included 11 Hurthle cell hyperplasias, 15 Hurthle cell adenomas, 29 Hurthle cell carcinomas, and 13 Hurthle cell variant papillary thyroid carcinomas. The analysis revealed cancer-related SNVs/indels in 14 of these samples, GFs in 6, CNAs in 27, and GEAs in 16 ( Table 2) . With the established threshold of 1.5, the classifier correctly detected 39 of 42 Hurthle cell cancers (92.9%). All 11 Hurthle cell hyperplasias had a classifier score of 0 and yielded a negative test result. Among Hurthle cell adenomas, 7 (46.7%) had a GC score of 0 to 1 (a negative test result), and 8 (53.3%) had a GC score of 2 to 4 (a positive test result; Fig. 3C ). Overall, for the oncocytic lesions included in the training tissue set, the ThyroSeq v3 GC Abbreviations: ATC, anaplastic thyroid carcinoma; CNA, copy number alteration; GEA, gene expression alteration; indel, insertion/deletion; NA, not applicable; NIFTP, noninvasive follicular thyroid neoplasm with papillary-like nuclear features; PDTC, poorly differentiated thyroid carcinoma; PTC, papillary thyroid carcinoma; SNV, single-nucleotide variant.
had a sensitivity of 92.9% (95% CI, 80.52%-98.50%) and a specificity of 69.3% (95% CI, 48.21%-85.67%). The validation FNA set included 5 benign Hurthle cell nodules (2 Hurthle cell hyperplasias and 3 Hurthle cell adenomas) and 9 cancers (2 Hurthle cell carcinomas and 7 Hurthle cell variant papillary thyroid carcinomas). All 9 cancers were detected, with the GC score ranging from 2 to 5. Among the benign Hurthle cell nodules, all 5 yielded a negative test result with a GC score of 0 to 1.
Sample Stability
The standard collection procedure for the ThyroSeq test includes collection of an FNA sample into a tube with a preservative solution and subsequent handling of the specimen at room temperature until shipment overnight in chilled boxes or storage at -208C for a longer period of time. To test the stability of sample DNA and RNA under different stressed conditions, 3 ex vivo FNA samples were created and tested in triplicate for different time and temperature conditions that simulated variations in FNA sample storage and shipping. The samples maintained acceptable quantity, quality, and purity of DNA and RNA materials under various tested conditions (Supporting Table 5 [see online supporting information]).
Next, we compared ThyroSeq performance in different sample types. Although FNA samples collected directly into a preservative solution have the highest quality of nucleic acids, this test can be performed on fixed FNA cells from a cytology cell block and on FFPE tissue samples. We performed a sequencing analysis of 20 normal and tumor FFPE samples and compared the quality of sequencing with that of 20 FNA samples collected into a preservative solution. Although FFPE samples showed on average a lower number of reads, this significantly exceeded the minimal acceptable depth of sequencing (500 reads) required for the assay (Fig. 4) .
Minimal Acceptable Nucleic Acid Input
The recommended input of nucleic acids for library preparations used for semiconductor sequencing technology according to the manufacturer's recommendation is 10 ng. We investigated the tolerance of the test results to variability in the nucleic acid quantity to determine the minimal acceptable input. Ten samples from cancer nodules (5 thyroid FNA samples and 5 FFPE resected tumor samples) were diluted at 10, 5, 2.5, 1, and 0.5 ng of nucleic acid input for library generation and sequencing. The ThyroSeq v3 GC was able to correctly identify genetic alterations and classify as positive 100% of samples, including both FNA and FFPE samples, with a nucleic acid input of 2.5 to 10 ng, whereas only 50% of the samples were correctly classified as positive with 1 ng (all FNA samples), and none of the samples were correctly classified as positive with a 0.5-ng input of nucleic acids (Supporting Table 6 [see online supporting information]). These results indicate that the minimal input of nucleic acids tolerated by the assay is 2.5 ng.
Minimal Acceptable Tumor Content
The proportion of neoplastic cells in thyroid FNA samples can have significant variability. To find the minimal acceptable tumor content yielding an accurate test result, we performed serial dilutions of DNA and RNA from 10 thyroid cancer samples (5 FNA samples and 5 tissue samples) in normal thyroid tissue samples. All 10 samples were correctly classified as positive down to the 12% tumor sample/88% normal thyroid sample dilution, whereas the proportion of correctly classified samples gradually decreased with further dilutions (Supporting Table 7 [see online supporting information]). Normal thyroid tissues were all classified as negative by GC. These data indicate that accurate ThyroSeq v3 GC performance should be expected as long as the collected thyroid FNA sample contains approximately 12% tumor cells in a background of nonneoplastic thyroid cells.
Dilution With Nonthyroidal Cells
Thyroid FNA samples may contain various amounts of blood and other cells, such as white blood cells, tissueinfiltrating lymphocytes, and stromal fibroblasts. To determine the minimal acceptable number of thyroid cells within an FNA sample, we used 3 thyroid cancer samples (1 FNA sample and 2 tissue samples). The samples were diluted in a mixture of whole-blood samples, and 24 in vitro mixtures with 8 concentrations of thyroid cells were created (Supporting Table 8 [see online supporting information]). The ThyroSeq v3 GC correctly classified mixtures down to 12% thyroid cells in all samples, down to 6% in 2 samples, and down to 3% in 2 samples and thus demonstrated that a 12% thyroid cell content is sufficient for correct classification. In addition, the samples were evaluated to define the test's tolerance to blood content or method specificity. The results demonstrated that the presence of blood did not interfere with any of the NGS analysis steps. Sample classification remained accurate up to a blood content of 88% (Supporting Table 8 [see online supporting information]). All undiluted blood samples were called negative by the GC.
In addition, assay reproducibility, repeatability, and reagent stability studies were performed and demonstrated high accuracy for the assay's performance (Supporting Table 4 [see online supporting information]).
DISCUSSION
In this study, we report the results of analytical validation of a new targeted NGS-based, multi-analyte test for thyroid FNA and tissue samples. The ThyroSeq v3 GC interrogates 5 different classes of molecular alterations and was created to further improve the sensitivity of cancer detection in comparison with the currently available molecular tests. 15, 16, 22 Indeed, in this study, the test, which was trained for maximum accuracy, achieved a sensitivity of 94% in the training set and a sensitivity of 98% in the validation set of samples. If this is confirmed in a prospective clinical validation study, it would suggest that even in populations with a high pretest disease prevalence, the residual cancer risk in thyroid nodules with negative test results could remain at a sufficiently low level for observation to be considered in lieu of surgical excision for many of these patients (https://www.nccn.org/).
We achieved a high sensitivity of cancer detection in this study by testing for multiple classes of genetic alterations and also by offering high analytical sensitivity for detecting various types of diagnostic alterations in thyroid FNA samples. Indeed, in comparison with the previous version of ThyroSeq, the current version has been expanded not only to include a larger number of genes tested for mutations, indels, fusions, and abnormal expression but also to examine CNAs. The importance of chromosomal copy number changes is that they are found in approximately 7% of papillary carcinomas lacking Original Article
